Microsoft PowerPoint - Roche IR Event EULAR Final.ppt

More documents

Recommendations

Info

Rates of serious infection Similar in patients with low and normal Ig levels Number of patients with low Ig at anytime All exposure n=1053 - Patients with normal IgG and IgM n=761 - Patients with low IgG at any time n=67 67/1053 (6.3%) Patients with low IgM at ant time n=261 261/1053 (24.7%) Patients with IgM
MabThera – Conclusions Sustained or improved efficacy with repeat treatment • Benefits of rituximab are sustained with repeated courses • Stopping joint damage progression remains a priority in inadequate responders to TNF inhibitors • REFLEX study provides first and only evidence of inhibition of structural joint damage in this patient population • This is independent of achieving a clinical response with rituximab Overall safety profile consistent with prior studies • Similar serious infection rates with repeat treatment courses – No opportunistic infections, viral reactivations or tuberculosis reported • No lymphoproliferative malignancies and no increased risk of malignancy with additional courses of treatment were observed • Long-term follow-up of RA patients receiving rituximab showed safety profile similar with each course 53
Page 2 and 3: Roche Analyst Meeting EULAR 2007 Ba
Page 4 and 5: Introduction Dr. Karl Mahler Head o
Page 6 and 7: Roche’s key therapeutic areas Cur
Page 8 and 9: RA: A very concentrated market 6.00
Page 10 and 11: Increased penetration of biologics
Page 12 and 13: Actemra: The OPTION trial results P
Page 14 and 15: Elevated IL-6 plays central role in
Page 16 and 17: The OPTION study TOcilizumab Pivota
Page 18 and 19: Demographics Intent-to-treat popula
Page 20 and 21: Results: Efficacy and safety 20
Page 22 and 23: Rapid onset of action with tocilizu
Page 24 and 25: Tocilizumab induces rapid CRP norma
Page 26 and 27: Most frequently reported AEs Incide
Page 28 and 29: Adverse events Consistent with thos
Page 30 and 31: MabThera: Longer-term repeat treatm
Page 32 and 33: Rituximab selectively targets CD20-
Page 34 and 35: Rituximab: Advancing in RA Initial
Page 36 and 37: Inhibition of radiographic progress
Page 38 and 39: Efficacy: Repeat treatment courses
Page 40 and 41: Patient exposure to repeat courses
Page 42 and 43: ACR scores are sustained Repeated c
Page 44 and 45: Consistent time intervals between t
Page 46 and 47: More than 2400 patient-years As of
Page 48 and 49: No increase in infection rates with
Page 50 and 51: IgM RF levels by treatment course o
Page 54 and 55: Roche’s franchise in autoimmune d
Page 56 and 57: Overview of autoimmune disorders IN
Page 58 and 59: Not all patients respond to current
Page 60 and 61: Major players are active in this ar
Page 62 and 63: Actemra Potential to become a signi
Page 64 and 65: Ocrelizumab in autoimmune diseases
Page 66 and 67: Multiple sclerosis An emerging ther
Page 68 and 69: Prevalence of MS in Europe ~260,000
Page 70 and 71: Development hurdles & treatment cha
Page 72 and 73: Roche in autoimmune disorders Roche

Microsoft PowerPoint - Roche IR Event EULAR Final.ppt

Create successful ePaper yourself

Delete template?

Save as template?